Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.

Pillarisetti S, Khanna I.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):143-58. Review.

PMID:
22280237
[PubMed - indexed for MEDLINE]
2.

Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.

Revermann M.

Curr Opin Pharmacol. 2010 Apr;10(2):173-8. doi: 10.1016/j.coph.2009.12.002. Epub 2010 Jan 14. Review.

PMID:
20079692
[PubMed - indexed for MEDLINE]
3.

Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.

Ni GH, Chen JF, Chen XP, Yang TL.

Pharmazie. 2011 Mar;66(3):153-7. Review.

PMID:
21553642
[PubMed - indexed for MEDLINE]
4.

Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.

Wagner K, Inceoglu B, Hammock BD.

Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):76-83. doi: 10.1016/j.prostaglandins.2011.08.001. Epub 2011 Aug 10. Review.

PMID:
21854866
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.

Elmarakby AA.

Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R321-30. doi: 10.1152/ajpregu.00606.2011. Epub 2011 Nov 23. Review.

PMID:
22116511
[PubMed - indexed for MEDLINE]
6.

Soluble epoxide hydrolase inhibitors and cardiovascular diseases.

Wang ZH, Davis BB, Jiang DQ, Zhao TT, Xu DY.

Curr Vasc Pharmacol. 2013 Jan;11(1):105-11. Review.

PMID:
22303912
[PubMed - indexed for MEDLINE]
7.
8.

Soluble epoxide hydrolase: a novel target for the treatment of hypertension.

Fang X.

Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):67-72. Review.

PMID:
18221075
[PubMed - indexed for MEDLINE]
9.

Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor.

Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM.

Am J Physiol Cell Physiol. 2012 Aug 1;303(3):C278-90. doi: 10.1152/ajpcell.00386.2011. Epub 2012 May 23.

PMID:
22621785
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.

Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD.

Life Sci. 2006 Nov 10;79(24):2311-9. Epub 2006 Aug 2.

PMID:
16962614
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.

Deng Y, Theken KN, Lee CR.

J Mol Cell Cardiol. 2010 Feb;48(2):331-41. doi: 10.1016/j.yjmcc.2009.10.022. Epub 2009 Nov 3. Review.

PMID:
19891972
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Vascular pharmacology of epoxyeicosatrienoic acids.

Pfister SL, Gauthier KM, Campbell WB.

Adv Pharmacol. 2010;60:27-59. doi: 10.1016/B978-0-12-385061-4.00002-7. Review.

PMID:
21081214
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.

Imig JD.

Cardiovasc Drug Rev. 2006 Summer;24(2):169-88. Review.

PMID:
16961727
[PubMed - indexed for MEDLINE]
14.

The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment.

Davis BB, Liu JY, Tancredi DJ, Wang L, Simon SI, Hammock BD, Pinkerton KE.

Biochem Biophys Res Commun. 2011 Jul 8;410(3):494-500. doi: 10.1016/j.bbrc.2011.06.008. Epub 2011 Jun 7.

PMID:
21683067
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Soluble epoxide hydrolase: gene structure, expression and deletion.

Harris TR, Hammock BD.

Gene. 2013 Sep 10;526(2):61-74. doi: 10.1016/j.gene.2013.05.008. Epub 2013 May 20. Review.

PMID:
23701967
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL.

J Pharmacol Exp Ther. 2008 Dec;327(3):707-15. doi: 10.1124/jpet.108.142398. Epub 2008 Sep 24.

PMID:
18815352
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Xu X, Zhang XA, Wang DW.

Adv Drug Deliv Rev. 2011 Jul 18;63(8):597-609. doi: 10.1016/j.addr.2011.03.006. Epub 2011 Apr 6. Review.

PMID:
21477627
[PubMed - indexed for MEDLINE]
18.

Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.

Chen G, Xu R, Wang Y, Wang P, Zhao G, Xu X, Gruzdev A, Zeldin DC, Wang DW.

Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E563-75. doi: 10.1152/ajpendo.00591.2011. Epub 2012 Jun 26.

PMID:
22739108
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.

Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD.

Biochem Pharmacol. 2010 Mar 15;79(6):880-7. doi: 10.1016/j.bcp.2009.10.025. Epub 2009 Nov 5.

PMID:
19896470
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.

Sun D, Cuevas AJ, Gotlinger K, Hwang SH, Hammock BD, Schwartzman ML, Huang A.

Am J Physiol Heart Circ Physiol. 2014 Apr 15;306(8):H1146-53. doi: 10.1152/ajpheart.00920.2013. Epub 2014 Feb 21.

PMID:
24561863
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk